Currus Biologics

Executive Summary

Currus Biologics is an Australian preclinical-stage biotech developing a proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) platform to overcome key limitations of CAR‑T and TCR therapies in solid tumours. By linking engineered T cells to professional antigen‑presenting cells in lymph nodes, BEAT aims to enhance T‑cell expansion, persistence, and tumour infiltration. The company was founded in 2020 and has raised $20M, leveraging expertise from the Peter MacCallum Cancer Centre. Its platform addresses the immunosuppressive tumour microenvironment and poor T‑cell trafficking, which have hindered adoptive cell therapies in solid tumours. Currus is advancing its lead candidate through preclinical studies, with a focus on generating in vivo proof‑of‑concept data to support an IND filing. The company's differentiated mechanism and strong scientific foundation position it as a promising player in next‑generation cell therapy.

Upcoming Catalysts (preview)

• Q3 2026Presentation of preclinical in vivo efficacy data at a major oncology conference60% success
• Q1 2027Completion of IND-enabling studies and filing of IND/CTA with regulatory authorities40% success
• Q4 2026Strategic partnership or licensing deal for BEAT platform with a larger biopharma company30% success